Fort Lauderdale, Florida, Feb. 18, 2025 (GLOBE NEWSWIRE) — Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) today announced that the underwriter of its previously announced initial public offering fully exercised its option to purchase an additional 3,000,000 units at the public offering price of $10.00 per unit, resulting in additional gross proceeds of $30,000,000. The units began trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “DMAAU” on January 28, 2025.